A Stock For Speculators 一只投机股票

AcelRx Pharmaceuticals, Inc.,(ACRX 1.92) a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

Positives for ACRX:

1. Products: DSUVIA has been approved by both FDA and EU, ACRX projected that DSUVIA may reach a peak annual sales of $1.1Billion.  ZALVISO has been approved by EU and it is in Phase 3 trial in US. The potential sales of both DSUVIA and ZALVISO are going to be huge for the  $218 millions capitalized company.

2. Sales and earnings: This quarter earning growth +60%, next year earning growth +55%.  Four analysts is for revenues of US$32.4m in 2021, which would reflect a huge 638% increase on its sales over the past 12 months. Losses are predicted to fall substantially, shrinking 56% to US$0.28. ACRX reports earning on February 4.

3. Analysts opinions: 4 analysts follow stock, 3 rated ACRS Buy, consensus price target is 4.95. Cantor analyst target is 9. 

4. Hedge fund trend: Increasing number of hedge fund buy into stock,there is a total of 5 hedge funds holding stock in Q3.

5. Technicals: Yesterday it had a big 60% up with near 26X average volume means strong upside momentum. Stock retrace a little and try to hold most  of yesterday's gain today. It broke above a downtrend line since 2018, trend has turned up. Next technical target is 2.5 then 3. Support is 1.7.

AcelRx Pharmaceuticals，Inc.（ACRX 1.92）是一家专业制药公司致力于治疗急性疼痛疗法的开发和商业化。该公司的主要候选产品是DSUVIA，一种30 mcg舒芬太尼舌下片剂，用于治疗中度至重度急性疼痛。它还开发了ZALVISO，ZALVISO是一种预编程的，患者控制的镇痛系统，可使患有中度至重度急性疼痛的住院患者自行服用舒芬太尼舌下片剂来减轻疼痛。该公司的前身为SuRx Pharmaceuticals，Inc.，并于2006年8月更名为AcelRx Pharmaceuticals，Inc.。AcelRx Pharmaceuticals，Inc.成立于2005年，总部位于加利福尼亚州红木城。

ACRX的优点：

 1.产品：DSUVIA已获得FDA和EU的批准，ACRX预计DSUVIA的年销售额达到峰值时会达到11亿美元。 ZALVISO已获欧盟批准，目前正在美国进行3期试验。DSUVIA和ZALVISO的潜在销售量对于这家市值只为2.18亿美元的公司来说影响会是巨大的。

 2.销售和收入：本季度收入估计增长+ 60％，明年收入增长+ 55％。到2021年，四位分析师的销售估计将达到3240万美元，这相较过去12个月的销售额大幅增长638％。预计亏损将大幅下降，减少56％至每股0.28美元。ACRX将于2月4日发布财报。

 3.分析师意见：4位分析师关注股票，3位对ACRS的评级为“买入”，共识目标价为4.97。Cantor分析师目标价最高为9。 

 4.对冲基金趋势：对冲基金购买股票的数量增加，第三季度共有5家对冲基金持有股票。

 5.技术面：昨日以接近26倍平均成交量大幅上涨60％意味着强劲的上涨动力。ZCRX并且向上突破自2018年以来的下跌趋势线，趋势转升。今天尝试着稳固而回调不多并保持昨日大部分涨幅。下一个技术目标是2.5，然后是3。支撑是1.7.